FRANKFURT, June 29, 2010 /PRNewswire/ -- Elsevier and Sapienza University of Rome today announced a new agreement, providing researchers at the university with access to Reaxys (, Elsevier's workflow solution for research chemists. Reflecting the way chemists think and work, Reaxys will enable researchers at Sapienza to quickly find the chemistry relevant for their needs and thereby raise their performance and output.

Marina Dalla Torre, Director of the Sapienza Chemistry Library, said of the purchase, From the first time we interacted with the product, it was clear that it was a completely different one - user friendly and liked by our students. The new access model also made possible to share this resource with the Department of Pharmacology, and we are sure that other departments will be interested as well.

Prof. Aldo Lagana, Sapienza's Head of Chemistry, added, My role is to support the sharing of chemistry knowledge and to provide researchers with the best way to improve their performances, particularly during this difficult economic period. Many colleagues have expressed their strong interest in Reaxys, and I believe that their work, and the department as a whole, will benefit from using it.

Offering experimentally validated information, Reaxys combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists.

We have invested considerable time and effort to ensure that Reaxys mirrors a chemist's research workflow said Mark van Mierle, Managing Director for Elsevier Information Systems. This, combined with a simple campus-wide access mechanism, will enable researchers to quickly identify the most important and relevant information.

About Sapienza University of Rome

La Sapienza University of Rome, is the first university in Rome and the largest in Europe. Founded in 1303, Sapienza has over 4500 professors and offers over 300 degree programmes. Sapienza plans and carries out important scientific investigations in almost all disciplines and has 23 faculties, 112 departments and 30 centres devoted to scientific research. High-standard results are achieved on both on a national and international level.

About Elsevier Properties SA

Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including Reaxys(R), PharmaPendium(TM) and The Lancet(R) are owned and protected by Elsevier Properties SA and used under license. For additional information see

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet ( and Cell (, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (, Scopus (, Reaxys (, MD Consult ( and Nursing Consult (, which enhance the productivity of science and health professionals, and the SciVal suite ( and MEDai's Pinpoint Review (, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Tom Reller Vice President, Global Corporate Relations +1-215-239-3508

SOURCE: Elsevier Properties and Elsevier

CONTACT: Tom Reller, Vice President, Global Corporate Relations,+1-215-239-3508,